Expression-Based Subtypes Define Pathologic Response to Neoadjuvant Immune-Checkpoint Inhibitors in Muscle-Invasive Bladder Cancer

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD00001007998	ATACseq FASTq files from RT4 cells treated with KDM5i C70	Illumina HiSeq 4000	4
EGAD00001007999	RNAseq FASTq files from RT4 cells treated with FGFRi Erdafitinib	Illumina NovaSeq 6000	6
EGAD00001008000	RNAseq FASTq files from RT4 cells treated with KDM5i C70	Illumina NovaSeq 6000	6
EGAD00001008001	single-cell RNAseq FASTq files for three muscle-invasive bladder tumors	Illumina HiSeq 2500	12
EGAD00001008002	RNAseq FASTq files from 31 post-treatment tumors from PURE01	Illumina HiSeq 2500	31
EGAD00001008003	RNAseq FASTq files from 82 pre-treatment tumors from PURE01	Illumina HiSeq 4000	82

Publications	Citations
Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer. Robertson AG, Meghani K, Cooley LF, McLaughlin KA, Fall LA, Yu Y, Castro MAA, Groeneveld CS, de Reyniès A, Nazarov VI, Tsvetkov VO, Choy B, Raggi D, Marandino L, Montorsi F, Powles T, Necchi A, Meeks JJ. Nat Commun 14: 2023 2126	19